Form 4: Regeneron SVP Controller Exercises Options, Sells Shares

Regeneron Pharmaceuticals' SVP Controller, Jason Pitofsky, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.

Summary

• Jason Pitofsky, SVP Controller of Regeneron Pharmaceuticals, Inc. (REGN), reported transactions on February 9, 2026.
• Pitofsky acquired 1,000 shares of common stock by exercising non-qualified stock options at an exercise price of $492 per share.
• Concurrently, Pitofsky sold a total of 1,974 shares of common stock in multiple transactions at volume-weighted average prices ranging from $775.95 to $785.72.
• All transactions were executed under a Rule 10b5-1(c) plan adopted on November 10, 2025.
• Following these transactions, Pitofsky directly holds 4,272 shares of common stock and indirectly holds 31 shares in a 401(k) Plan and 179 shares by his spouse.
• Pitofsky also holds 905 non-qualified stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While there is a net reduction in direct share ownership, the transactions are part of a pre-scheduled 10b5-1 plan, which is a routine event for executives managing their equity compensation.

Positives

• The exercise of stock options indicates a prior grant of equity compensation, which is a common incentive for executives.
• The transactions were conducted under a Rule 10b5-1 plan, indicating pre-planned sales and reducing concerns about opportunistic insider trading.

Negatives

• The net effect of the transactions is a reduction in direct beneficial ownership of common stock by 974 shares (1,000 acquired 1,974 sold).
• Insider selling, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence, though this is mitigated by the pre-planned nature.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common in the pharmaceutical industry as a means for executives to manage their equity compensation and diversify their personal holdings in a compliant manner. These transactions typically do not reflect a change in the company's operational outlook.

Stakeholder Impact

• Shareholders: The net sale of shares by an executive could be perceived neutrally to slightly negatively, but the 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions executed under a pre-arranged 10b5-1 plan. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The net sale of shares is a common practice for executives managing their equity compensation and does not inherently signal a negative outlook for the company. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Regeneron Pharmaceuticals, REGN, Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Jason Pitofsky, SVP Controller, Equity Compensation